Premium
Pterostilbene Inhibits VEGF Production in Human Breast Cancer [MDA‐MB‐231] Cells
Author(s) -
Sanghani Arpitkumar,
Kandra Theja,
Bavadekar Supriya,
Vansal Sandeep
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1104.6
Subject(s) - pterostilbene , resveratrol , angiogenesis , matrix metalloproteinase , vascular endothelial growth factor , cancer research , pharmacology , breast cancer , cancer , interleukin 8 , mcf 7 , apoptosis , chemistry , medicine , vegf receptors , cytokine , human breast , biochemistry
Pterostilbene, a stilbenoid and natural analog of resveratrol, is present mainly in blueberries, and has been shown to have anticancer, anti‐inflammatory, and antioxidant properties in various cancer cell lines. However the anti‐angiogenic potential of pterostilbene has not yet been established in breast cancer. The objective of this research was to investigate the effect of pterostilbene on pro‐angiogenic factors including vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMP‐2 and MMP‐9), and inflammatory cytokines (IL‐6 and IL‐8) in human metastatic, breast cancer cells, MDA‐MB‐231. The cells were treated with increasing concentrations of pterostilbene ranging from 10 μM to 100 μM for 24hr, and secreted VEGF concentrations were measured using ELISA. Pterostilbene caused a dose‐dependent decrease of secreted VEGF [~45% inhibition at 100 μM] when compared with control. Further studies are underway to understand the molecular mechanism involved. These results indicate that pterostilbene possesses anti‐angiogenic properties that may critically contribute to its observed anticancer effects. This work is supported by the Division of Pharmaceutical Sciences at Long Island University and the Touro College of Pharmacy.